Growth factor signalling networks in breast cancer and resistance to endocrine agents: New therapeutic strategies

Journal of Steroid Biochemistry and Molecular Biology

Volumn 93, Issue 2-5, 2005, Pages 257-262

  Nicholson, R I ^a   Hutcheson, I R ^a   Britton, D ^a   Knowlden, J M ^a   Jones, H E ^a   Harper, M E ^a   Hiscox, S E ^a   Barrow, D ^a   Gee, J M W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; EGFR; Endocrine and gefitinib resistance; Gefitinib; HER2; IGF IR; Tamoxifen

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; FULVESTRANT; GEFITINIB; GROWTH FACTOR; RECEPTOR BLOCKING AGENT; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CELL; CELL MOTILITY; CONFERENCE PAPER; DISEASE COURSE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TREATMENT FAILURE;

EID: 18044379750     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2004.12.006     Document Type: Conference Paper

References (49)

1. R.I. Nicholson, and J.M. Gee Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer Br. J. Cancer 82 2000
2. R.I. Nicholson, I.R. Hutcheson, M.E. Harper, J.M. Knowlden, D. Barrow, R.A. McClelland, H.E. Jones, A.E. Wakeling, and J.M. Gee Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer Endocr. Relat. Cancer 8 2001 175 182
3. A.E. Wakeling, R.I. Nicholson, and J.M. Gee Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin. Cancer Res. 7 Suppl. 12 2001 4350s 4355s (discussion 4411s-4412s)
4. R.I. Nicholson, I.R. Hutcheson, J.M. Knowlden, H.E. Jones, M.E. Harper, N. Jordan, S.E. Hiscox, D. Barrow, and J.M. Gee Nonendocrine pathways in endocrine resistance: observarions with antiestrogens and signal transduction inhibitors in combination Clin. Cancer Res. 10 2004 346S 354S
5. R.A. McClelland, D. Barrow, T.A. Madden, C.M. Dutkowski, J. Pamment, J.M. Knowlden, J.M. Gee, and R.I. Nicholson Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex) Endocrinology 142 2001 2776 2788
6. J.M. Knowlden, I.R. Hutcheson, H.E. Jones, T. Madden, J.M. Gee, M.E. Harper, D. Barrow, A.E. Wakeling, and R.I. Nicholson Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 144 2003 1032 1044
7. I.R. Hutcheson, R.A. McClelland, J.M. Knowlden, D. Barrow, A.E. Wakeling, J.M.W. Gee, and R.I. Nicholson Increased sensitivity of tamoxifen- and fulvestrant-resistant MCF-7 breast cancer cells to the growth inhibitory action of ZD1839 ('Iressa') First International Symposium on Signal Transduction Modulators in Cancer Therapy Proceedings 1 2002 18
8. J.M. Gee, J.F. Robertson, I.O. Ellis, and R.I. Nicholson Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer Int. J. Cancer 4 2001 247 254
9. A. Bonni, A. Brunet, A.E. West, S.R. Datta, M.A. Takasu, and M.E. Greenberg Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms Science 286 1999 1358 1362
10. S. Gibson, S. Tu, R. Oyer, S.M. Anderson, and G.L. Johnson Epidermal growth factor protects epithelial cells against Fas-induced apoptosis requirement for Akt activation J. Biol. Chem. 274 1999 17612 17618
11. V. Stambolic, T.W. Mak, and J.R. Woodgett Modulation of cellular apoptotic potential: contributions to oncogenesis Oncogene 18 1999 6094 6103
12. R.A. Campbell, P. Bhat-Nakshatri, N.M. Patel, D. Constantinidou, S. Ali, and H. Nakshatri Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance J. Biol. Chem. 276 2001 9817 9824
13. I.R. Hutcheson, J.M. Knowlden, T.A. Madden, D. Barrow, J.M.W. Gee, A.E. Wakeling, and R.I. Nicholson Oestrogen receptor mediated modulation of the EGFR/MAPK pathway in tamoxifen resistant MCF-7 cells Breast Cancer Res. Treat. 81 2003 81 93
14. S. Kato, H. Endo, Y. Masuhiro, T. Kitamoto, S. Uchiyama, H. Sasaki, S. Masushige, Y. Gotoh, E. Nishida, H. Kawashima, D. Metzger, and P. Chambon Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase Science 270 1995 1491 1494
15. G. Bunone, P.A. Briand, R.J. Miksicek, and D. Picard Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation EMBO J. 15 1996 2174 2183
16. S. Ali, D. Metzger, J.M. Bornert, and P. Chambon Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region EMBO J. 12 1993 1153 1160
17. D. Britton, I.R. Hutcheson, D. Barrow, J.M.W. Gee, and R.I. Nicholson Increased oestrogen receptor phosphorylation at serine 118 in tamoxifen resistant MCF-7 breast cancer cells Biochem. Soc. Trans. 31 2002 P114
18. L.A. Martin, I. Farmer, S.R. Johnston, S. Ali, C.J. Marshall, and M. Dowsett Enhanced ERalpha ERBB2 and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term oestrogen deprivation Biol. Chem. 29 May 2003
19. C.M. Chan, L.A. Martin, S.R. Johnston, S. Ali, and M. Dowsett Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation J. Steroid Biochem. Mol. Biol. 81 2002 333 341
20. D. Yee, and A.V. Lee Crosstalk between the insulin-like growth factors and estrogens in breast cancer J. Mammary Gland Biol. Neoplasia 5 2000 107 115
21. I.H. Hamelers, and P.H. Steenbergh Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells Endocr. Relat. Cancer 10 2003 331 345
22. M.A. Guvakova, and E. Surmacz Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells Cancer Res. 57 1997 2606 2610
23. H.E. Jones, L. Goddard, J.M.W. Gee, S. Hiscox, M. Rubini, D. Barrow, S. Williams, A.E. Wakeling, and R.I. Nicholson Insulin-like growth -1 receptor signalling and acquired resistance to gefitinib (ZD1839, Iressa) in human breast and prostate cancer cells Endocr. Relat. Cancer 11 2004 793 814
24. S. Hiscox, A.E. Wakeling, and R.I. Nicholson Inhibition of the metastatic potential of tamoxifen-resistant breast cancer cells by gefitinib ('Iressa' AZ1839) Clin. Exp. Met. 2004
25. A. Wells Tumor invasion: role of growth factor-induced cell motility Adv. Cancer Res. 78 2000 31 101
26. C.J. Barnes, R. Bagheri-Yarmand, M. Mandal, Z. Yang, G.L. Clayman, W.K. Hong, and R. Kumar Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa) Mol. Cancer Ther. 2 2003 345 351
27. M. Ranson, and ZD1839 (Iressa™): for more than just non-small cell lung cancer Oncologist 7 2002 16 24
28. F.M. Sirotnak Studies with ZD1839 in preclinical models Semin. Oncol. 30 Suppl. 1 2003 12 20
29. T. van Agthoven, T.L. van Agthoven, A. Dekker, J.A. Foekens, and L.C. Dorssers Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations Mol. Endocrinol. 8 1994 1474 1483
30. R.I. Nicholson, R.A. McClelland, P. Finlay, C.L. Eaton, W.J. Gullick, A.R. Dixon, J.F. Robertson, I.O. Ellis, and R.W. Blamey Relationship between EGF-R, c-erbB-2 protein expression and Ki-67 immunostaining in breast cancer and hormone sensitivity Eur. J. Cancer 29A 1993 1018 1023
31. R.I. Nicholson, R.A. McClelland, J.M. Gee, D.L. Manning, P. Cannon, J.F. Robertson, I.O. Ellis, and R.W. Blamey Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy Breast Cancer Res. Treat. 29 1994 117 125
32. R.I. Nicholson, R.A. McClelland, J.M. Gee, D.L. Manning, P. Cannon, J.F. Robertson, I.O. Ellis, and R.W. Blamey Transforming growth factor-alpha and endocrine sensitivity in breast cancer Cancer Res. 54 1994 1684 1689
33. R.I. Nicholson, J.M. Gee, and M.E. Harper EGFR and cancer prognosis Eur. J. Cancer 37 2001 9 15
34. J.G. Klijn, M.P. Look, H. Portengen, J. Alexieva-Figusch, W.L. van Putten, and J.A. Foekens The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 years follow-up study Breast Cancer Res. Treat. 29 1994 73 83
35. H. Mueller, N. Flury, S. Eppenberger-Castori, W. Kueng, F. David, and U. Eppenberger Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients Int. J. Cancer (Pred. Oncol.) 89 2000 384 388
36. J.M.W. Gee, T.A. Madden, J.F.R. Robertson, and R.I. Nicholson Clinical response and resistance to SERMS J.F.R. Robertson R.I. Nicholson D.F. Hayes Endocrine Therapy in Breast Cancer 2002 Martin Dunitz Ltd. London 155 190
37. G. Perez-Tenorio, O. Stal Southeast Sweden Breast Cancer Group Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients Br. J. Cancer 86 2002 540 545
38. D.A. Tonetti, M. Morrow, N. Kidwai, A. Gupta, and S. Badve Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure Br. J. Cancer 88 2003 1400 1402
39. J.F.R. Robertson, E. Gutteridge, K.L. Cheung, R. Owers, M. Koehler, L. Hamilton, J. Gee, and R.I. Nicholson Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study ASCO 2003
40. E. Gutteridge, J.M. Gee, K.I. Nicholson, and J.F.R. Robertson ASCO Annual Meeting Proceedings vol. 22 2004 p. 648
41. J. Baselga, J. Albanell, A. Ruiz, A. Lluch, P. Gascon, S. Gonzalez, V. Guillen, S. Sauleda, S. Averbuch, and F. Rojo Phase II and tumor pharmacodynamic study of gefinitib (ZD1839) in patients with advanced breast cancer ASCO 2003
42. K. Scotlandi, C. Maini, M.C. Manara, S. Benini, M. Serra, V. Cerisano, R. Strammiello, N. Baldini, P.L. Lollini, P. Nanni, G. Nicoletti, and P. Picci Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells Cancer Gene Ther. 9 2002 296 307
43. R. Bianco, I. Shin, C.A. Ritter, F.M. Yakes, A. Basso, N. Rosen, J. Tsurutani, P.A. Dennis, G.B. Mills, and C.L. Arteaga Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Oncogene 22 2003 2812 2822
44. Y. Lu, X. Zi, Y. Zhao, D. Mascarenhas, and M. Pollak Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J. Natl. Cancer Inst. 93 2001 1852 1857
45. A. Camirand, Y. Lu, and M. Pollak Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells Med. Sci. Monit. 8 2002 BR521 BR526
46. J.M.W. Gee, M.E. Harper, I.R. Hutcheson, T.A. Madden, D. Barrow, J.M. Knowlden, R.A. McClelland, N. Jordan, A.E. Wakeling, and R.I. Nicholson ZD1839 ('Iressa') improves the antitumour activity of tamoxifen ('Nolvadex') and ICI 182780 ('Faslodex') in antihormone responsive breast cancer Eur. J. Cancer 38 Suppl. 7 2002 59 (Abstract)
47. J.M.W. Gee, M.E. Harper, I.R. Hutcheson, T.A. Madden, D. Barrow, J.M. Knowlden, R.A. McClelland, N. Jordan, A.E. Wakeling, and R.I. Nicholson The anti-EGFR agent gefitinib (ZD1839/Iressa™) improves anti-hormone response and prevents development of resistance in breast cancer in vitro Endocrinology 144 2003 5105 5117
48. R.I. Yarden, M.A. Wilson, and S.A. Chrysogelos Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth J. Cell. Biochem. 81 2001 232 246
49. S. Massarweh, J. Shou, S.K. Mohsin, M. Ge, A.E. Wakeling, C.K. Osborne, and R. Schiff Inhibition of epidermal growth factor/HER2 receptor signalling using ZD1839 ("Iressa") restores tamoxifen sensitivity and delays resistance to oestrogen deprivation in HER2-overexpressing breast tumours Proc. Am. Soc. Clin. Oncol. 21 2002 33 (Abstract)